GET DAILY SIGNALSCardinal Health (CAH): A Look at One of the Key Players in Healthcare Distribution
Key Takeaways
- Cardinal Health, Inc. (CAH) is a global healthcare services and products company headquartered in Dublin, Ohio.
- The company operates two main reportable segments: Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD), alongside growth businesses in nuclear medicine, at-home solutions, and logistics.
- Cardinal Health is one of the largest pharmaceutical distributors in the United States, serving hospitals, pharmacies, and healthcare providers.
- The company generates most of its revenue from pharmaceutical distribution, a high-volume, relatively low-margin business.
- Cardinal Health competes primarily with other major drug distributors such as MCK (McKesson) and COR (Cencora).
Introduction
Cardinal Health, Inc. sits at the center of the medical supply chain as a diversified healthcare services and products company. It links pharmaceutical manufacturers, healthcare providers, pharmacies, and patients by handling the distribution of medicines and the production of medical products used in hospitals, clinics, and homes. Because healthcare spending tends to be non-discretionary, I view exposure to Cardinal Health as one way to tap into steady, recurring demand across the system. The stock trades on the New York Stock Exchange under the ticker CAH.
Company Profile and Business Model
Cardinal Health traces its roots to 1971, when founder Robert D. Walter started a food wholesaling business that later shifted toward healthcare distribution. The company was incorporated in 1979 and is now headquartered in Dublin, Ohio. It has grown through organic expansion and acquisitions to become one of the largest participants in the U.S. pharmaceutical distribution market. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The business model focuses on moving pharmaceuticals and medical products at large scale. Its Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty pharmaceuticals, and over-the-counter healthcare and consumer products, mainly in the United States. This segment drives most revenue and includes specialty pharmacy services, manufacturer services, and a nuclear pharmacy network.
The Global Medical Products and Distribution (GMPD) segment manufactures, sources, and distributes Cardinal Health–branded medical, surgical, and laboratory products such as exam and surgical gloves, needles and syringes, surgical drapes and gowns, fluid suction systems, and wound care products. These items reach markets in the United States, Canada, Europe, Asia, and elsewhere.
Beyond the two main segments, the company runs growth businesses under “Other,” including nuclear and precision health solutions, at-home solutions, and OptiFreight Logistics. This mix helps broaden its profile beyond core distribution.
How Cardinal Health Generates Revenue
Pharmaceutical distribution accounts for the bulk of total sales and represents a high-volume business with thin margins, as the company largely serves as an intermediary between manufacturers and pharmacies or hospitals. Profitability hinges on scale, supply-chain efficiency, and services like specialty logistics. The medical products segment and growth businesses generally deliver higher margins than core distribution. Healthcare demand tends to hold up across economic cycles, which supports relatively stable revenue even when pricing pressure or regulatory shifts affect results year to year.
Why Investors Track CAH
Investors follow Cardinal Health for several reasons. The company operates in a structurally growing market fueled by an aging population, rising demand for specialty and chronic-disease medications, and greater healthcare utilization. Its scale and distribution network create meaningful barriers to entry, while relationships with manufacturers and providers place it at the center of the supply chain. Cardinal Health has also moved into higher-growth areas such as specialty pharmaceuticals, nuclear medicine, and at-home care, which management sees as routes to better margins and diversification. The company pays a quarterly dividend and has used share repurchases in its capital allocation, which can appeal to income-focused and long-term investors. As one of the “big three” U.S. drug distributors alongside McKesson and Cencora, its performance serves as a useful indicator of pharmaceutical market activity.
Risks and Key Considerations
Several risks warrant attention. Pharmaceutical distribution is a low-margin business sensitive to drug pricing, generic-drug deflation, and reimbursement changes, including government pricing policies. Customer concentration stands out, since losing a major pharmacy or health-system contract can meaningfully affect revenue. The company also carries regulatory and legal exposure, including past litigation and settlements tied to opioid distribution. Operational risks include supply-chain disruptions, tariffs on imported medical products, and inflation in labor and transportation costs. Competition from McKesson, Cencora, and others remains strong, and technological or market shifts could pressure the traditional distribution model over time.
Conclusion
Cardinal Health plays a foundational role in the U.S. healthcare supply chain, marked by its scale in pharmaceutical distribution and its growing portfolio of medical products and higher-growth services. Its central position connecting manufacturers, providers, and patients supports a durable market stance, even as thin margins and regulatory factors shape financial outcomes. For investors, CAH provides exposure to broad, resilient healthcare demand alongside the risks of a large-scale, tightly regulated distribution business.
Exploring Tools for Stock Research
When I want to compare companies like Cardinal Health against peers or screen for ideas that match a specific strategy, I turn to Tickeron’s AI Screener. It uses technical indicators, fundamentals, volatility, trends, and AI signals to help narrow down opportunities across stocks and ETFs. This kind of platform can streamline the research process and surface ideas that align with an investor’s approach.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for CAH turns positive, indicating new upward trend
CAH saw its Momentum Indicator move above the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In 65 of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 32 of 47 cases where CAH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
CAH moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CAH crossed bullishly above the 50-day moving average on October 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 58%.
Following a +2.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAH advanced for three days, in 264 of 396 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 188 of 310 cases where CAH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Bearish Trend Analysis
The 10-day RSI Indicator for CAH moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 22 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
The Moving Average Convergence Divergence Histogram (MACD) for CAH turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 26 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
CAH broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 18 (best 1 - 100 worst), indicating outstanding price growth. CAH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-20.428) is normal, around the industry mean (12.613). CAH has a moderately high P/E Ratio (34.983) as compared to the industry average of (10.633). Projected Growth (PEG Ratio) (1.105) is also within normal values, averaging (2.016). Dividend Yield (0.008) settles around the average of (0.138) among similar stocks. P/S Ratio (0.217) is also within normal values, averaging (4.260).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of pharmaceuticals, medical, surgical and laboratory supplies as well as develops drug delivery systems
Industry MedicalDistributors
Advertisement